To overcome the deficiency that no known MDS or AML cell lines acquired endogenous U2AF1S34F mutation for inhibitor evaluation, we tested SF1–8 in primary MDS patient cells carrying U2AF1S34F (VAF, 41%) and found SF1–8 also inhibited the proliferation of the primary cells. This evidence concerns the gene SF1 and myelodysplastic syndrome.